Shares of Health Catalyst, Inc. (NASDAQ:HCAT – Get Free Report) have received a consensus recommendation of “Hold” from the thirteen analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $2.7727.
HCAT has been the subject of several research reports. Wells Fargo & Company reissued an “equal weight” rating and issued a $1.00 target price (down from $5.00) on shares of Health Catalyst in a research report on Wednesday, March 18th. Citigroup decreased their target price on Health Catalyst from $2.75 to $1.75 and set a “neutral” rating for the company in a research report on Friday, March 13th. Cantor Fitzgerald reissued a “neutral” rating on shares of Health Catalyst in a research report on Monday, May 11th. Canaccord Genuity Group decreased their target price on Health Catalyst from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, March 13th. Finally, Stifel Nicolaus decreased their target price on Health Catalyst from $3.75 to $2.00 and set a “hold” rating for the company in a research report on Friday, March 13th.
Get Our Latest Stock Report on HCAT
Institutional Inflows and Outflows
Health Catalyst Trading Down 2.9%
HCAT opened at $1.35 on Friday. The business has a 50 day simple moving average of $1.26 and a two-hundred day simple moving average of $1.87. The firm has a market capitalization of $99.75 million, a price-to-earnings ratio of -0.36 and a beta of 1.66. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.69 and a quick ratio of 1.69. Health Catalyst has a one year low of $0.96 and a one year high of $4.29.
Health Catalyst (NASDAQ:HCAT – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.01. Health Catalyst had a negative return on equity of 3.52% and a negative net margin of 87.69%.The firm had revenue of $70.76 million during the quarter, compared to analyst estimates of $69.24 million. Analysts predict that Health Catalyst will post -0.25 EPS for the current year.
Health Catalyst Company Profile
Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.
The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.
Featured Stories
- Five stocks we like better than Health Catalyst
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
